231例伴高滴度抑制物的重型血友病A患儿免疫耐受诱导成功预测因素——PedNet前瞻性队列研究的经验
该研究基于PedNet前瞻性队列,回顾了231例伴高滴度FVIII抑制物的重型血友病A患儿接受至少1个疗程免疫耐受诱导(ITI)的结局。首次ITI成功由ITI前抑制物峰值滴度、抑制物家族史、高危F8基因变异及抑制物诊断后10个月内启动ITI预测;ITI前峰值滴度5-39 BU者耐受率76.4%,40-200 BU者70.9%,>200 BU者42.1%。ITI方案(每日或非每日、高或低剂量)不是首次ITI成功的预测因素。
要点
- ITI前抑制物峰值滴度5-39 BU者耐受率76.4%,40-200 BU者70.9%,>200 BU者42.1%。
- 首次ITI期间峰值滴度>200 BU是最终ITI失败的强预测因素。
- ITI方案(每日或非每日、高或低剂量)不是首次ITI成功的预测因素。
核心结论
- ITI前抑制物峰值滴度、抑制物家族史、高危F8基因变异及抑制物诊断后10个月内启动ITI可预测首次ITI成功。
- 首次ITI期间峰值滴度>200 BU是最终ITI失败的强预测因素。
- 这些成功预测因素可用于在非替代预防治疗可及的情况下决定是否及如何启动ITI。
研究设计与样本
- PedNet前瞻性队列研究,回顾了231例伴高滴度FVIII抑制物的重型血友病A既往未治疗患者,随访20年,均接受至少1个疗程ITI。
主要发现
- ITI前峰值滴度5-39 BU者76.4%达到耐受(中位0.72年),40-200 BU者70.9%(中位2.1年),>200 BU者42.1%(中位5.1年)。
- 首次ITI成功由ITI前峰值滴度、抑制物家族史、高危F8基因变异及抑制物诊断后10个月内启动ITI预测。
- 首次ITI期间峰值滴度>200 BU是最终ITI失败的强预测因素。
- ITI方案(每日或非每日、高或低剂量)不是首次ITI成功的预测因素。
临床怎么用
- 作者认为这些成功预测因素可用于在非替代预防治疗可及的情况下决定是否及如何启动ITI。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previously untreated patients with severe hemophilia A exposed to factor (F)VIII are at risk of developing high-titer inhibitors. Traditionally, such children were tried on immune tolerance induction (ITI). With availability of nonfactor therapies, recommendations regarding whether to continue trying ITI and how are lacking. OBJECTIVES: To provide data to address these questions, we reviewed the experience of ITI in Pediatric Network (PedNet) centers. METHODS: The outcomes of 231 previously untreated patients with severe hemophilia A and high-titer inhibitors to FVIII, who were followed over a 20-year period and underwent ≥1 course of ITI, were reviewed. RESULTS: The success of the first course of ITI was predicted by pre-ITI peak inhibitor titers (PITs), a family history of inhibitors, high-risk F8 gene variants, and the start of ITI within 10 months of inhibitor diagnosis. Pre-ITI PITs were a strong predictor of eventual ITI success with 1 or more ITI courses: 76.4% of those with pre-ITI PITs of 5 to 39 Bethesda Units (BUs) achieved tolerance (median, 0.72 years) vs 70.9% of those with pre-ITI PITs of 40 to 200 BU (median, 2.1 years) vs 42.1% of those with pre-ITI PITs of >200 BU (median, 5.1 years). A PIT of >200 BU during the first course of ITI was a strong predictor of ultimately failing ITI. The ITI regimen, whether administered daily or nondaily at a high or low dose, was not a predictor of ITI success with the first course of ITI. CONCLUSION: These predictors of success may be used to decide whether and how to initiate ITI when nonreplacement prophylaxis is available.
引用
- Carcao M, Königs C, Andersson NG, et al. Predictors of immune tolerance induction success in 231 children with severe hemophilia A with high-titer inhibitors - lessons learned from the PedNet prospective cohort study. J Thromb Haemost. 2025. PMID: 40706963. doi:10.1016/j.jtha.2025.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。